[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342316-105":59,"doc-detail-342316-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeted-degradation-of-oncogenic-krasg12v-triggers-antitumor-immunity-in-lung-cancer-models","Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models","","Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently mutated in lung adenocarcinoma, with G12C and G12V predominating. Limited progress on KRASG12V reflects a shortage of specific inhibitors. Using the degradation tag (dTAG) system, the study builds a KRASG12V-transgenic mouse model to test KRASG12V-targeted degradation. Degrading KRASG12V abolishes lung and pancreatic tumors, suppresses KRAS-regulated cancer-intrinsic signaling, reprograms the tumor microenvironment, and drives antitumor immunity mainly via effector cytotoxic CD8+ T cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeted-degradation-of-oncogenic-krasg12v-triggers-antitumor-immunity-in-lung-cancer-models/342316/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeted-degradation-of-oncogenic-krasg12v-triggers-antitumor-immunity-in-lung-cancer-models/342316.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is KRASG12V targeting difficult compared with KRASG12C?","Question",{"text":112,"@type":113},"KRAS has historically been difficult to target directly, and progress for KRASG12V has been limited partly due to a lack of specific inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What method does the study use to target KRASG12V?",{"text":117,"@type":113},"The study uses the degradation tag (dTAG) system to develop a KRASG12V-transgenic mouse model enabling targeted KRASG12V degradation.",{"name":119,"@type":110,"acceptedAnswer":120},"How does KRASG12V degradation affect the tumor microenvironment and immunity?",{"text":121,"@type":113},"Targeted degradation reprograms the tumor microenvironment toward a stimulatory milieu and drives antitumor immunity, mainly mediated by effector cytotoxic CD8+ T cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342316,1790915889,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nTargeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models  \nDezhi Li,1 Ke Geng,1 Yuan Hao,2 Jiajia Gu,3 Saurav Kumar,4 Annabel T. Olson,4 Christina C. Kuismi,4 Hye Mi Kim,3,5 Yuanwang Pan,1 Fiona Sherman,1 Asia M. Williams,3,5 Yiting Li,3,6 Fei Li,7,8 Ting Chen,1 Cassandra Thakurdin,1 Michela Ranieri,1 Mary Meynardie,1 Daniel S. Levin,1 Janaye Stephens,1 Alison Chafitz,1 Joy Chen,4 Mia S. Donald-Paladino,4 Jaylen M. Powell,1 Ze-Yan Zhang,9 Wei Chen,10 Magdalena Ploszaj,1 Han Han,1 Shengqing Stan Gu,11 Tinghu Zhang,12 Baoli Hu,3,13 Benjamin A. Nacev,3,14,15  \nMedard Ernest Kaiza,3,5 Alice H. Berger,4 Xuerui Wang,3,5 Jing Li,3,5 Xuejiao Sun,3 Yang Liu,16 Xiaoyang Zhang,17 Tullia C. Bruno,3,5 Nathanael S. Gray,12 Behnam Nabet,4,18 Kwok-Kin Wong,1 and Hua Zhang3,14  \n1Division of Hematology and Medical Oncology, Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York, USA. 2Applied Bioinformatics Laboratories, Office of Science and Research, New York University Grossman School of Medicine, New York, New York, USA. 3Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA. 4Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. 5Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 6School of Medicine, Tsinghua University, Beijing, China. 7Department of Pathology, School of Basic Medical Sciences, and 8Frontier Innovation Center, School of Basic Medical Sciences, Fudan University, Shanghai, China. 9Department of Radiation Oncology, New York University Grossman School of Medicine, New York, New York, USA. 10Division of Pulmonary Medicine, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh and University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 11Department of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 12Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, California, USA. 13Department of Neurological Surgery, 14Department of Medicine, Division of Hematology/Oncology, and 15Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 16Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. 17Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. 18Department of Pharmacology, University of Washington, Seattle, Washington, USA.  \nKirsten rat sarcoma viral oncogene homolog (KRAS) is the most frequently mutated oncogene in lung adenocarcinoma, with G12C and G12V being the most predominant forms. Recent breakthroughs in KRASG12C inhibitors have transformed the clinical management of patients with the G12C mutation and advanced our understanding of the function of this mutation. However, little is known about the targeted disruption of KRASG12V, partly due to a lack of specific inhibitors. Here, we leverage the degradation tag (dTAG) system to develop a KRASG12V-transgenic mouse model. We explored the therapeutic potential of KRASG12V degradation and characterized its effect on the tumor microenvironment (TME). Our study reveals that degradation of KRASG12V abolished lung and pancreatic tumors in mice and caused a robust inhibition of KRAS-regulated cancer-intrinsic signaling. Importantly, targeted degradation of KRASG12V reprogrammed the TME toward a stimulatory milieu and drove antitumor immunity, elicited mainly by effector and cytotoxic CD8+ T cells. Our work provides insights into the effect of KRASG12V degradation on both tumor progression and the immune response, highlighting degraders as a powerful strategy for targeting KRAS-mutant cancers.  \nIntroduction  \nNon–small cell lung cancer (NSCLC) is one of t","cbCaii7AO9DnA2fx","https://ap.wps.com/l/cbCaii7AO9DnA2fx","pdf",15320072,15,"English","# Introduction\n## Study rationale and background on KRAS mutations\n## Approach using dTAG and KRASG12V degradation\n## Therapeutic effects on tumors and signaling\n## Immune reprogramming and CD8+ T-cell responses","[{\"question\":\"Why is KRASG12V targeting difficult compared with KRASG12C?\",\"answer\":\"KRAS has historically been difficult to target directly, and progress for KRASG12V has been limited partly due to a lack of specific inhibitors.\"},{\"question\":\"What method does the study use to target KRASG12V?\",\"answer\":\"The study uses the degradation tag (dTAG) system to develop a KRASG12V-transgenic mouse model enabling targeted KRASG12V degradation.\"},{\"question\":\"How does KRASG12V degradation affect the tumor microenvironment and immunity?\",\"answer\":\"Targeted degradation reprograms the tumor microenvironment toward a stimulatory milieu and drives antitumor immunity, mainly mediated by effector cytotoxic CD8+ T cells.\"}]","Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models | PDF",1790046113,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb288d563a718d6c2c0b1d88883c2e41.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94f813b96265ef4e8153dd0fb0421f61.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4efc4d0ef896c1f46559d6d4578a18d.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd454927e10d43f7fc14ce1a8f835500.webp",980,1311]